| Autor: |
Vitoon Chinswangwatanakul, Atthaphorn Trakarnsanga, Varut Lohsiriwat, Chotirot Angkurawaranon, Pattarachai Kiratisin, Amorn Leelaratsamee, Darin Lohsiriwat |
| Zdroj: |
Thai Journal of Surgery; Apr-Jun2013, Vol. 34 Issue 2, p51-55, 5p |
| Abstrakt: |
Purpose: To evaluate the efficacy and safety of intravenous single-agent antibiotic Cefoperazone/Sulbactam for the treatment of bacterial infection among surgical patients. Methods: This prospective opened non-comparative clinical trial was conducted in the Department of Surgery, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand from 1 October 2008 to 30 September 2009. Therapeutic Cefoperazone/Sulbactam (Sulcef®) at the dose of 1.5 grams was given intravenously every 12 hours to patients with bacterial infection who needed emergency or elective surgical interventions, and the APACHE II score was equal or less than 15. All patients were scheduled for follow-up visits at 7, 14 and 30 days after the first dose of intravenous Cefoperazone/Sulbactam for monitoring the clinical outcomes. Results: Thirty-five patients were enrolled and 31 patients had completed the follow up. There were 17 males and 14 females with the mean age of 53 years (range 20-85 years). The clinical efficacy of Cefoperazone/Sulbactam to improve or cure patients was 87%, whereas the bacterial eradication rate was 84%. Neither drug-related serious adverse reaction nor drug allergy was observed. Conclusions: Cefoperazone/Sulbactam demonstrated broad-spectrum antibacterial coverage in patients infected with gram-positive, gram-negative and anaerobic bacteria. Intravenous Cefoperazone/Sulbactam is safe and effective for empirical treatment of bacterial infection among surgical patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
